Solomon, Benjamin J., Zhou, Cai Cun, Drilon, Alexander, Park, Keunchil, Wolf, Jurgen, Elamin, Yasir, Davis, Hannah M., Soldatenkova, Victoria, Sashegyi, Andreas, Lin, Aimee Bence, Lin, Boris K., Loong, Herbert H., Novello, Silvia, Arriola, Edurne, Perol, Maurice, Goto, Koichi and Santini, Fernando C. . Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol.. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Solomon, Benjamin J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhou, Cai CunUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Drilon, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Park, KeunchilUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, JurgenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Elamin, YasirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Davis, Hannah M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Soldatenkova, VictoriaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sashegyi, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lin, Aimee BenceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lin, Boris K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loong, Herbert H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Novello, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arriola, EdurneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Perol, MauriceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goto, KoichiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Santini, Fernando C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-312170
DOI: 10.2217/fon-2020-0935
Journal or Publication Title: Future Oncol.
Publisher: FUTURE MEDICINE LTD
Place of Publication: LONDON
ISSN: 1744-8301
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ALK; REARRANGEMENTS; EFFICACY; FUSIONS; IPILIMUMAB; MUTATIONS; BLOCKADE; NSCLC; EGFR; BRAFMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31217

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item